Tingting Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tingting Xu has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Chaosu Hu
Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
54 shared publications - Xueguan Lu
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Clinical Research Center for Radiation Oncology, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China
53 shared publications - Xiayun He
Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai China
49 shared publications - Qinghai Ji
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
48 shared publications - Xiaomin Ou
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
48 shared publications - Bin Wu
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
39 shared publications
Latest Publications
- Open Access
Integrating Pretreatment Circulating Tumor HPV DNA and Tumor Volume for Risk Stratification in HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Background: Circulating tumor HPV DNA (ctHPV DNA) has shown clinical value in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), but its relationship with tumor burden and its role in prognosis, especially when combined with clinicoradiological factors, remain to be further defined. Methods: We analyzed 103 patients with HPV-positive OPSCC enrolled in an observational biomarker study, most of whom received induction chemotherapy or chemoimmunotherapy followed by definitive radiotherapy. Blood samples were collected at pretreatment, post-radiotherapy, and follow-up time points, and ctHPV DNA levels were quantified using droplet digital PCR. Baseline clinicoradiological parameters from contrast-enhanced MR or CT and 18F-FDG PET/CT were analyzed for their association with ctHPV DNA levels and clinical outcomes. Results: Baseline ctHPV DNA correlated with primary tumor volume (VT), nodal volume (VN), total tumor volume (VT+N), and the number of involved primary tumor sites and lymph node regions, particularly LN-related features. VT and maximum LN diameter were independent predictors of baseline ctHPV DNA. Detectable follow-up ctHPV DNA was associated with inferior progression-free survival but showed low sensitivity and positive predictive value for relapse detection. Integrative stratification using baseline ctHPV DNA and VT+N identified a potential high-risk subgroup with high tumor volume but paradoxically low ctHPV DNA (VOLhighDNAlow). Exploratory RNA-seq analysis was performed to investigate potential biological features underlying this discordance, and a seven-gene signature associated with PFS was identified. Conclusions: These findings suggest that baseline ctHPV DNA reflects tumor burden and may provide additional information for upfront risk stratification in HPV-positive OPSCC, warranting further validation in larger prospective cohorts.
Open AccessIntegrating Pretreatment Circulating Tumor HPV DNA and Tumor Volume for Risk Stratification in HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Background: Circulating tumor HPV DNA (ctHPV DNA) has shown clinical value in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), but its relationship with tumor burden and its role in prognosis, especially when combined with clinicoradiological factors, remain to be further defined. Methods: We analyzed 103 patients with HPV-positive OPSCC enrolled in an observational biomarker study, most of whom received induction chemotherapy or chemoimmunotherapy followed by definitive radiotherapy. Blood samples were collected at pretreatment, post-radiotherapy, and follow-up time points, and ctHPV DNA levels were quantified using droplet digital PCR. Baseline clinicoradiological parameters from contrast-enhanced MR or CT and 18F-FDG PET/CT were analyzed for their association with ctHPV DNA levels and clinical outcomes. Results: Baseline ctHPV DNA correlated with primary tumor volume (VT), nodal volume (VN), total tumor volume (VT+N), and the number of involved primary tumor sites and lymph node regions, particularly LN-related features. VT and maximum LN diameter were independent predictors of baseline ctHPV DNA. Detectable follow-up ctHPV DNA was associated with inferior progression-free survival but showed low sensitivity and positive predictive value for relapse detection. Integrative stratification using baseline ctHPV DNA and VT+N identified a potential high-risk subgroup with high tumor volume but paradoxically low ctHPV DNA (VOLhighDNAlow). Exploratory RNA-seq analysis was performed to investigate potential biological features underlying this discordance, and a seven-gene signature associated with PFS was identified. Conclusions: These findings suggest that baseline ctHPV DNA reflects tumor burden and may provide additional information for upfront risk stratification in HPV-positive OPSCC, warranting further validation in larger prospective cohorts.
- Open Access
- 8 April 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study
In this phase 3 trial, penpulimab combined with chemotherapy was assessed against a regimen of placebo plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). 291 patients were randomised and allocated in a 1:1 ratio in order to receive penpulimab (n = 144; 200 mg) or placebo (n = 147; 200 mg), plus chemotherapy (cisplatin/carboplatin and gemcitabine) every 3 weeks. Patients followed by maintenance therapy with penpulimab or placebo after 6 cycles. The primary endpoint of this study was progression-free survival (PFS) according to RECIST v1.1, and a significantly longer median PFS in the penpulimab arm versus the placebo arm (9.63 versus 7.00 months; hazard ratio 0.45, 95% CI: 0.33-0.62, P < 0.0001) was demonstrated in this prespecified interim analysis. The key secondary endpoint was the overall survival (OS). However, the OS data were still immature, and the median OS was not achieved (hazard ratio, 0.94; 95% CI: 0.63-1.40). The occurrence of treatment-related adverse events (grade ≥ 3) was 89.0% and 85.9% in two arms, with the most common being reduced the quantity of neutrophil (56.2% vs. 62.0%), reduced the quantity of white blood cell (54.1% vs. 54.9%), and anemia (45.2% vs. 38.7%). In the penpulimab arm, 6 patients (4.1%) experienced immune-related adverse events (grade ≥ 3). Adding penpulimab to chemotherapy led to a notable enhancement in PFS for the first-line R/M NPC treatment, alongside a safety profile that was both manageable and tolerable. ClinicalTrials.gov identifier NCT04974398.
- 8 April 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Open AccessAnti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study
In this phase 3 trial, penpulimab combined with chemotherapy was assessed against a regimen of placebo plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). 291 patients were randomised and allocated in a 1:1 ratio in order to receive penpulimab (n = 144; 200 mg) or placebo (n = 147; 200 mg), plus chemotherapy (cisplatin/carboplatin and gemcitabine) every 3 weeks. Patients followed by maintenance therapy with penpulimab or placebo after 6 cycles. The primary endpoint of this study was progression-free survival (PFS) according to RECIST v1.1, and a significantly longer median PFS in the penpulimab arm versus the placebo arm (9.63 versus 7.00 months; hazard ratio 0.45, 95% CI: 0.33-0.62, P < 0.0001) was demonstrated in this prespecified interim analysis. The key secondary endpoint was the overall survival (OS). However, the OS data were still immature, and the median OS was not achieved (hazard ratio, 0.94; 95% CI: 0.63-1.40). The occurrence of treatment-related adverse events (grade ≥ 3) was 89.0% and 85.9% in two arms, with the most common being reduced the quantity of neutrophil (56.2% vs. 62.0%), reduced the quantity of white blood cell (54.1% vs. 54.9%), and anemia (45.2% vs. 38.7%). In the penpulimab arm, 6 patients (4.1%) experienced immune-related adverse events (grade ≥ 3). Adding penpulimab to chemotherapy led to a notable enhancement in PFS for the first-line R/M NPC treatment, alongside a safety profile that was both manageable and tolerable. ClinicalTrials.gov identifier NCT04974398.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
Supplementary Table 1 from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
Supplementary Table 1 from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
Supplementary figures and legends
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
Supplementary figures and legends
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
The Differential Expression of Various Genes between the Resistant and Sensitive Groups
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
The Differential Expression of Various Genes between the Resistant and Sensitive Groups
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Comparative Analysis of Peripheral Lymphocyte Subpopulations Before Treatment in the Sensitive and Resistant Groups
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Comparative Analysis of Peripheral Lymphocyte Subpopulations Before Treatment in the Sensitive and Resistant Groups
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Overall response rate of induction chemoimmunotherapy (N=27)
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Overall response rate of induction chemoimmunotherapy (N=27)